In phase I/IIa clinical trial using the NOGATM mapping system, autologous G-CSF mobilized PB-CD34+ therapy improved the frequency of angina, exercise tolerance, and CCS scale, providing preliminary evidence of the immunity and bioactivity of CD34+ cell injection in patients with refractory angina (Losordo et al., 2007). This evidence concerns the gene CD34 and angina pectoris.